Birtamimab + Standard of Care Chemotherapy
Phase 3Terminated 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Light Chain (AL) Amyloidosis
Conditions
Light Chain (AL) Amyloidosis
Trial Timeline
Aug 30, 2021 → Jun 20, 2025
NCT ID
NCT04973137About Birtamimab + Standard of Care Chemotherapy
Birtamimab + Standard of Care Chemotherapy is a phase 3 stage product being developed by Prothena for Light Chain (AL) Amyloidosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT04973137. Target conditions include Light Chain (AL) Amyloidosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04973137 | Phase 3 | Terminated |
Competing Products
5 competing products in Light Chain (AL) Amyloidosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ABBV-383 (Etentamig) | AbbVie | Phase 1/2 | 41 |
| Linvoseltamab | Regeneron Pharmaceuticals | Phase 1/2 | 40 |
| Afamelanotide (CUV1647) | Clinuvel Pharmaceuticals | Pre-clinical | 15 |
| Afamelanotide + Placebo | Clinuvel Pharmaceuticals | Phase 3 | 69 |
| NXC-201 CAR-T | Immix Biopharma | Phase 1/2 | 33 |